GT Biopharma Receives FDA Clearance to Commence First-in-Human Phase 1 Study of its First-in-Class Tri-Specific Killer Engager (TriKE), GTB-3550, for the Treatment of Acute Myelogenous Leukemia, Myelodysplatic Syndrome and Mastocytosis November 1, 2018
GT Biopharma's Chairman and Chief Executive Officer, Raymond W Urbanski MD, PhD, Provides Further Insight into the Recent Activity in the Natural Killer Cell (NK) Space October 4, 2018
GT Biopharma Announces Postive Results For Two Next Generation Trikes In Solid Tumors September 13, 2018
GT Biopharma's Chairman and Chief Executive Officer Raymond W Urbanski, M.D., Ph.D Provides Insight Into the Impact of the Recent Affimed/Roche-Genetech Collaboration August 30, 2018
GT Biopharma's Chairman and Chief Executive Officer Provides Insight Into the Impact of the Recent Affimed/Roche-Genetech Collaboration August 29, 2018
GT Biopharma Announces Initiation of OXS-1550 in Combination With a Multi-billion Dollar Oncology Drug August 28, 2018
GT Biopharma Announces the Appointment of David Cardino, CPA, MBA as Vice President of Finance August 24, 2018
GT Biopharma Announces GTBP CEO, Dr. Raymond Urbanski, to Make Presentation at the 2018 Wedbush PacGrow Healthcare Conference August 14, 2018
